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Simultaneous Enrichment of Cysteine-
containing Peptides and Phosphopeptides
Using a Cysteine-specific Phosphonate
Adaptable Tag (CysPAT) in Combination with
titanium dioxide (TiO2) Chromatography*□S
Honggang Huang‡§**, Martin Haar Petersen‡¶, Maria Ibañez-Vea‡, Pernille S. Lassen‡,
Martin R. Larsen‡‡‡**, and Giuseppe Palmisano‡**‡‡
Cysteine is a rare and conserved amino acid involved in
most cellular functions. The thiol group of cysteine can be
subjected to diverse oxidative modifications that regulate
many physio-pathological states. In the present work, a
Cysteine-specific Phosphonate Adaptable Tag (CysPAT)
was synthesized to selectively label cysteine-containing
peptides (Cys peptides) followed by their enrichment with
titanium dioxide (TiO2) and subsequent mass spectromet-
ric analysis. The CysPAT strategy was developed using a
synthetic peptide, a standard protein and subsequently
the strategy was applied to protein lysates from Hela
cells, achieving high specificity and enrichment efficiency.
In particular, for Cys proteome analysis, the method led to
the identification of 7509 unique Cys peptides from 500 g
of HeLa cell lysate starting material. Furthermore, the
method was developed to simultaneously enrich Cys pep-
tides and phosphorylated peptides. This strategy was ap-
plied to SILAC labeled Hela cells subjected to 5 min epi-
dermal growth factor (EGF) stimulation. In total, 10440
unique reversibly modified Cys peptides (3855 proteins)
and 7339 unique phosphopeptides (2234 proteins) were
simultaneously identified from 250 g starting material.
Significant regulation was observed in both phosphoryla-
tion and reversible Cys modification of proteins involved
in EGFR signaling. Our data indicates that EGF stimulation
can activate the well-known phosphorylation of EGFR and
downstream signaling molecules, such as mitogen-acti-
vated protein kinases (MAPK1 and MAPK3), however, it
also leads to substantial modulation of reversible cysteine
modifications in numerous proteins. Several protein tyro-
sine phosphatases (PTPs) showed a reduction of the cat-
alytic Cys site in the conserved putative phosphatase
HC(X)5R motif indicating an activation and subsequent
de-phosphorylation of proteins involved in the EGF sig-
naling pathway. Overall, the CysPAT strategy is a straight
forward, easy and promising method for studying redox
proteomics and the simultaneous enrichment strategy of-
fers an excellent solution for characterization of cross-
talk between phosphorylation and redox induced revers-
ible cysteine modifications. Molecular & Cellular
Proteomics 15: 10.1074/mcp.M115.054551, 3282–3296,
2016.
Cysteine (Cys) is the second rarest amino acid, after tryp-
tophan, with 214,000 Cys encoded by the human genome (1).
However, it is highly conserved and widely present in more
than 97% of human proteins suggesting its important regula-
tory role in biological systems (2). The thiol group (R-SH) of
Cys residues can function as reversible redox switches in
proteins through oxidative post-translational modifications
(oxPTMs)1 by reactive species in the cell. The common
oxPTMs of Cys include reversible disulfides, thiosulfinates,
S-glutathionylation, sulfenic acids, sulfenamides, sulfin-
amides, S-nitrosylation, and irreversible oxidative forms such
as sulfinic acids, sulfonic acids, and sulfonamides (3). The
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switch to regulate protein structure, activity, interactions and
localization, and reflects the cellular redox state. The improper
balance of the cellular redox state is related to various dis-
eases such as diabetes, cardiovascular disease, neurodegen-
erative disorders and cancer (4).
The challenges associated with the characterization of the
reversible Cys modifications, which are often substoichiomet-
ric and labile has prompted toward the development of many
analytical strategies (2, 3). Two-dimensional gel-based fluo-
rescent detection of reversible oxPTMs of Cys residues have
complemented large scale mass spectrometry-based analy-
ses (5). Site-directed characterization of Cys residues has
been largely based on reaction of the Cys residues with
reagents bearing an enrichment moiety by alkylation or reduc-
tion switch. The first large scale study of Cys peptides was
achieved using isotope coded affinity tags (ICAT) with a biotin
tag (6). However, the strong affinity constant between biotin/
avidin limits the fully elution of labeled peptides from the resin.
Moreover, the large biotin tag generates fragments in the
tandem mass spectrometric (MS/MS) analysis, complicating
the interpretation of spectra and subsequent peptide identifi-
cation (7). Nowadays photo and chemical-cleavable ICAT al-
ternatives have been reported (8, 9). The biotin affinity tag was
also used in the biotin switch assay to study Cys S-nitrosy-
lation modifications (10). The chemical workflow adopted in
the biotin switch assay served as guide to develop several
enrichment methods toward oxidative modified Cys peptides
(11). It should be noted that the biotin switch assay is an
indirect method and recently novel chemicals have been ex-
plored to directly tag oxidatively modified cysteines (12, 13).
Cys reactive tandem mass tag (Cys-TMT) switch assay has
been developed to identify and quantify S-nitrosylation in
biological sample (14, 15). The enrichment in the Cys-TMT
method is based on an anti-TMT antibody resin. The concept
of “fluorous proteomics” is based on peptide tagging with
perfluorinated moieties and subsequent enrichment by solid-
phase extraction using a fluorous-functionalized stationary
phase (16). The versatility of fluorous tags was shown toward
different PTMs such as primary amine, phosphopeptides and
cysteine-containing peptides (16). However, recovery of en-
riched labeled peptides from the fluorous solid-phase media
is in the range of 50–55% (16). Recently, thiol-affinity enrich-
ment of Cys peptides was introduced (17) and it employs
thiol-reactive resins to capture and enrich cysteines with high
specificity and efficiency (17–19).
Titanium dioxide (TiO2) chromatographic resin is widely
used for enrichment of phosphorylated peptides with high
efficiency and specificity (20, 21). the enrichment mechanism
is the adsorption of phospho-group to the surface of TiO2 by
forming a bridging bidentate surface complex (22). Recently,
we introduced the concept of using phospho-based adapta-
ble tags (PATs) in combination with TiO2 enrichment for iden-
tification and characterization of specific PTMs and applied
the concept for the enrichment of O-GlcNAcylated peptides
using a click chemistry-based phosphate tag (23, 24). Later,
N-terminal peptide enrichment using phosphor-tagging and
TiO2-based enrichment was shown (25). The PAT tags contain
a specific reactive group and a phospho-group (e.g. phos-
phate or phosphonate), the reactive group can chemo-selec-
tively react with the target chemical group in proteins or
peptides, and the phospho-group enables the enrichment
using TiO2 or other phospho-enrichment resins.
In this study we developed a novel Cysteine-specific Phos-
phonate Adaptable Tag (CysPAT) for enrichment and charac-
terization of Cys peptides and reversible modified Cys pep-
tides in combination with differential reduction and alkylation.
The CysPAT was synthesized by a reaction between N-Suc-
cinimidyl iodoacetate (SIA) and 2-aminoethylphosphonic acid
(2-AEP). The synthesized tag was used to selectively label
Cys peptides with a phosphonate tag before enrichment with
TiO2 and subsequent mass spectrometric analysis. The
CysPAT strategy was developed using a synthetic peptide, a
standard protein and subsequently the strategy was applied
to detect total Cys residuals from Hela cells lysate, achieving
very high specificity and enrichment efficiency. The strategy
was further developed to simultaneously enrich Cys peptides
and phosphorylated peptides from SILAC labeled Hela cells
subject to 5 min epidermal growth factor (EGF) stimulation,
demonstrating high enrichment specificity for both PTMs and
offering the possibility to detect free radical induced alteration
in reversible Cys and to study the cross-talk between phos-
phorylation and reversible Cys modifications during cellular
signaling.
EXPERIMENTAL PROCEDURES
Materials—All chemicals were purchased from Sigma-Aldrich (St.
Louis, MO), unless otherwise stated. Modified trypsin was from Pro-
mega (Madison, WI). Poros R2 and Poros Oligo R3 reversed-phase
material were from Applied Biosystems (Forster city, CA). GELoader
tips were from Eppendorf (Hamburg, Germany). The 3 M EmporeTM
C8 disk was from 3 M Bioanalytical Technologies (St. Paul, MN).
Titanium dioxide beads were a gentle gift from GL Sciences Inc.
(Tokyo, Japan). N-Succinimidyl Iodoacetate (SIA) was purchased
from Thermo Scientific (Rockford, IL). Alkaline phosphatase, PNGase
F and endoprotease Asp-N were obtained from New England Biolabs
(Ipswich,MA). Glyko® Sialidase C™ was from Prozyme (Hayward,
CA). All solutions were made with ultrapure Milli-Q water (Millipore,
Bedford, MA).
Standard Peptide and Bovine Serum Albumin (BSA) Protein—The
standard Cys peptide VALHCLAL was a generous gift of Prof. Peter
Hojrup (University of Southern Denmark, DK), synthesized by solid
phase peptide synthesis and dissolved in 50 mM triethylammonium
bicarbonate buffer (TEAB). Bovine serum albumin (BSA) (0.5 mg) was
dissolved in 200 l 50 mM triethylammonium bicarbonate buffer
(TEAB), pH 7.8, reduced with 10 mM TCEP for 1h at room temperature
and digested with trypsin (1–2%, w/w) at 37 °C for 12 h, then desalted
and purified with a self-packed R3 column for further use.
Cell Culture—Human cervix epithelial adenocarcinoma (HeLa) cells
were cultured and maintained in 15 cm cell culture dishes in Dulbec-
co’s Modified Eagle Medium (DMEM)  Glutamax media (Gibco,
Waltham, MA) supplemented with 10% Fetal Bovine Serum (Sigma)
and 1% penicillin/streptomycin (Invitrogen, Grand Island, NY). Cells
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were maintained at 37 °C in a humidified atmosphere containing 5%
CO2. For the epidermal growth factor (EGF) stimulated stable isotope
labeling using amino acids in cell culture (SILAC) HeLa cell experi-
ment, HeLa cells were cultured for six cells divisions in DMEM SILAC
light or heavy media supplemented with 10% FBS, 1% Glutamax and
1% penicillin/streptomycin and L-Met, L-Pro and Arg (Arg-0 or Arg-10)
and Lys (Lys-0 or Lys-8). Prior to stimulation, cells were serum
starved for 18 h at 80% confluence. Cells were stimulated with 150 ng
ml-1 EGF in DMEM for 5 min. Then the cultures were washed with
ice-cold phosphate buffer saline (PBS), followed by scraping the cells
off the plate and pelleted by centrifugation. The remaining PBS was
removed and the pellets were snap-frozen in liquid nitrogen. The
pellets were stored at 80 °C until further sample preparation.
Chemical Synthesis of Cysteine-specific Phosphonate Adaptable
Tag (CysPAT)—Firstly, for reagent solutions, 1 mg (3.53 mol) SIA
and 2 mg (15.99 mol) 2-aminoethylphosphonic acid (2-AEP) was
dissolved in 10 l dimethyl sulfoxide (DMSO) and 150 l 50 mM TEAB,
respectively. The two reagent solutions were carefully mixed, adding
the water-containing solution drop by drop to the DMSO solution and
mixing. The final pH should be adjusted to 7.5 by adding 1 M TEAB,
and the final volume was adjusted to 200 l with 50 mM TEAB buffer.
The reaction would happen immediately after mixing; if precipitation
appears, it should be re-suspended by vortexing or pipetting up and
down. The reaction is taken place in the dark for 1 h at room tem-
perature to yield the CysPAT tag (2-(2-iodoacetamido) ethyl) phos-
phonic acid. The CysPAT tag should be freshly prepared before use
and kept in the dark.
For Detection of Total Cys Residuals—HeLa cells derived from one
plate were re-suspended in 500 l lysis buffer containing 6 M urea, 2
M thiourea, 2% sodium dodecyl sulfate (SDS), complete protease
inhibitor (Roche, Hvidovre, Denmark, one tablet per 50 ml), and lysed
on ice using a probe sonicator and centrifuged for 10 min at 2000 
g. The supernatant was collected and subjected to 10 KDa spin filter
to remove SDS. The precipitated protein pellet was redissolved in 100
l urea-buffer (6 M Urea, 2 M Thiourea), and the proteins were reduced
with 10 mM tris(2-carboxyethyl)phosphine (TCEP) for 1h at room
temperature. No alkylation step was performed here. The reduced
proteins were subsequently digested with 0.04 AU Lys-C (Wako,
Japan) for 3 h at room temperature. After Lys-C digestion, the solution
was diluted eight times with 50 mM TEAB buffer to 0.75 M urea and
0.25 M Thiourea, and trypsin (2%, w/w) was added for further diges-
tion at 37 °C overnight. The digested peptides were desalted and
purified with an OASIS HLB column (Waters, Millford, MA) and the
eluted peptides were lyophilized and subsequently resuspended in
200 l 50 mM TEAB buffer, and the concentration was measured
using Qubit assay (Invitrogen). A total of 500 g of peptides were
used in the experiments. The peptides were further treated with 20 U
of alkaline phosphatase, 1 l PNGase F and 0.5 l sialidase C at
37 °C for 3 h to perform the dephosphorylation and deglycosylation in
order to avoid simultaneous enrichment of phosphorylated peptides
and sialylated glycopeptides in the TiO2 enrichment step.
Preparation of Protein Lysate from EGF Stimulated SILAC Labeled
HeLa Cells—The EGF stimulated SILAC Hela cells with light or heavy
SILAC (EGF stimulated) labeling were re-suspended in 500 l lysis
buffer containing 6 M urea, 2 M thiourea, 2% SDS, 40 mM NEM,
complete protease inhibitor (Roche, one tablet per 50 ml) and phos-
phatase inhibitor PhosStop (Roche, two tablets per 50 ml), and lysed
on ice using a probe tip sonicator. After using 10 kDa spin filters to
remove SDS and unreacted NEM, the protein concentration was
determined by Qubit. A total of 250 g of protein from light and heavy
SILAC labeled Hela cells were pooled together and these samples
were prepared in triplicate from three individual stimulation experi-
ments. The following reduction, digestion were performed the same
way as described for total Cys residuals, but without the dephospho-
rylation step.
Labeling of Cys Peptides with Synthesized CysPAT—For the stan-
dard peptide, 0.1 g peptide was mixed with 5 molar ratio of the
above prepared reaction buffer containing synthesized CysPAT. Pep-
tides from 500 g BSA, 500 g HeLa cell protein extract for total Cys
residuals and the coenrichment experiment, respectively, were mixed
with 10 mM of the synthesized CysPAT in 50 mM TEAB, pH 7.8 in a
volume of 200 l. The mixed solution was incubated in the dark for 1 h
with gentle agitation. Afterward, the solution was subjected to OASIS
HLB column or Oligo R3 Reversed phase micro-column purification to
purify the peptides and remove extra chemicals. The eluted peptides
were lyophilized.
TiO2 Enrichment—TiO2 enrichment was performed to enrich the
CysPAT labeled Cys peptides as previously described for phosphor-
ylated peptides (20, 21). A total of 0.6 mg TiO2 per 100 g peptides
was used for total Cys peptides. For coenrichment of both reversible
Cys modified peptides and phosphopeptides, a total of 1.4 mg TiO2
per 100 g peptides was added to ensure efficient enrichment of both
modified peptide sets.
The labeled peptides were dissolved in 100 l 0.1% TFA, and then
diluted 10 times with loading buffer of 80% ACN, 5% TFA and 1 M
glycolic acid. Proper amount of TiO2 beads as described above was
added to the solution, shaken for 10 min at 600 rpm and centrifuged.
The supernatant was collected carefully and incubated with half the
amount of TiO2. The TiO2 beads were first washed with 100 l of
loading buffer by mixing for 15 s, transferred to a new tube and
centrifuged to pellet the beads, then washed with 100 l of a solution
containing 80% ACN and 1% TFA, and followed by washing with 100
l of a solution containing 20% ACN and 0.1% TFA. The peptides
were eluted with 50 l eluting buffer (40 l 28% ammonia solution in
960 l water, pH 11.3) and centrifuged for 1 min. The eluent was
collected and passed through a C8 stage tip to remove TiO2 beads
and the peptides attached to the C8 tip were subsequently eluted
with 1 l 30% ACN. The enriched phosphorous peptides were
acidified using formic acid, and desalted using a Poros Oligo R3
microcolumn. The desalted eluent was lyophilized prior to HILIC
fractionation.
MALDI-TOF-MS—The standard peptide with or without phospho-
tag labeling, and the labeled standard peptide spiked in normal BSA
peptides before and after TiO2 enrichment were all desalted by re-
versed phase Poros Oligo R3 reversed-phase material staged in
GELoader tips. Retained peptides were eluted onto a stainless-steel
target plate using ACN/0.1% TFA (70:30, v/v) containing 5 mg/ml
-CHCA. Mass spectra were acquired on an Ultraflex II MALDI-TOF/
TOF (tandem TOF) mass spectrometer controlled by flexControl soft-
ware (version 2.4, Bruker Daltonics, Bremen, Germany). The instru-
ment was operated in the positive reflector ion detection mode, and
spectra were recorded in the mass range ofm/z 500–4000. Typically,
signals from 1000 laser shots (10  100 shots at 10 different posi-
tions) were averaged. Spectra were externally calibrated using a
tryptic lactoglobulin. Mass spectra were analyzed with flex- Analysis
software (version 2.4, Bruker Daltonics). For MALDI-TOF/TOF analy-
sis, the window for precursor ion selection was set to be 1% of the
mass of the precursor ion.
Hydrophilic Interaction Liquid Interaction Chromatography (HILIC)—
Enriched peptides from HeLa cells were further fractionated using
HILIC. Enriched peptides were fractionated on an in-house packed
TSKgel Amide-80 HILIC (Tosoh Bioscience, 5 m) 320 m 170 mm
HPLC column by using the Agilent 1200 micro-HPLC instrument
(26). Briefly, samples were suspended in solvent B (90% ACN, 0.1%
TFA) by adding 10% TFA followed by water and finally the acetonitrile
was slowly added to the aqueous solution in order to prevent peptide
precipitation by the high acetonitrile concentration. Peptides were
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loaded onto a 320 ID peak HILIC column and eluted at 6 l/min by
decreasing the solvent B concentration (100–60% ACN, 0.1%TFAin-
water) in 42 min. Fractions were automatically collected in a 96 well
plate at 1 min intervals after UV detection at 210 nm and dried by
vacuum centrifugation, and stored at 20 °C until LC-MS/MS
analysis.
Mass Spectrometric Detection—Cysteine-containing peptides
from BSA and HeLa cells for total Cys residuals were analyzed with a
nanoEasy LC combined with a LTQ Orbitrap Velos mass spectrom-
eter (Thermo Fisher Scientific). HILIC fractions were resuspended in
0.1% FA and loaded onto a 2 cm 100 ID pre-column using a nano-
Easy LC (Thermo Fisher Scientific). Peptides were eluted directly onto
the analytical column using a gradient of 0% to 34% buffer B (90%
Acetonitrile, 0.1% FA) over 70 min. All LC-MS/MS runs were per-
formed using an analytical column of 20 cm  75 m inner diameter
fused silica, packed with C18 material (Dr. Maisch, Ammerbuch-
Entringen, Germany). Mass spectrometry was performed using higher
energy collision fragmentation (HCD) fragmentation on a Thermo LTQ
Orbitrap Velos. MS settings: A full MS scan in the mass area of
400–1800 Da was performed in the Orbitrap with a resolution of
30,000 FWHM and a target value of 1  106 ions. For each full scan
the seven most intense ions (1 charge state) were selected for
higher energy collision dissociation (HCD) and detected at a resolu-
tion of 7500 FWHM. The settings for the HCD were as follows:
threshold for ion selection was 20,000, the target value of ions used
for HCD was 1  105, activation time was 10 ms, isolation window
was 2.5 Da, and normalized collision energy was 34.
Reversibly modified Cys peptides and phosphopeptides from the
simultaneous enrichment experiment were analyzed by an Orbitrap
Fusion Tribrid™ Mass Spectrometer (Thermo Fisher Scientific). Pep-
tides were resuspended in 5 l of 0.1% TFA to their analysis. Peptides
were loaded on an Acclaim PepMap100 C18 Nano-trap column (2
cm  100 m, 5 m, 100 Å) using 0.1% TFA and separated on an
in-house packed Reprosil-Pur C18-AQ (3 m; Dr. Maisch GmbH)
analytical column (20 cm  75 m) at using a Dionex Ultimate® 3000
Nano LC system (Thermo Scientific) and eluted at a flow of 250
nL/min. Mobile phase was acetonitrile (B) and water (A) both contain-
ing 0.1% formic acid. Depending on the samples, gradient was
0–34% solvent B in 90 min, 34–100% B in 5 min, and 8 min at 100%
B. Eluting peptides were analyzed on an Orbitrap Fusion. Survey
scans of peptide precursors from 350 to 1400 m/z were performed at
120,000 resolution (at 200 m/z) with a 5  10e5 ion count target, the
max injection time was 60 ms. Tandem MS was performed by isola-
tion at 1.6 Th with the quadrupole, HCD fragmentation with normal-
ized collision energy of 38, and MS2 analysis in the Orbitrap. The MS2
resolution was set to 30,000 and the max injection time was 100 ms.
Only those precursors with charge state 2, 3, and 4 were sam-
pled for MS2. The dynamic exclusion duration was set to 30 s with a
10 ppm tolerance around the selected precursor. The instrument was
run in top speed mode with 3 s cycles, meaning the instrument would
continuously perform MS2 events until the list of nonexcluded pre-
cursors diminishes to zero or 3 s, whichever is shorter. Raw data were
submitted to pride (http://www.ebi.ac.uk/pride/archive/) under the
project accession PXD002704 (username: reviewer18039@ebi.ac.uk,
password: t5mWGpOb).
Bioinformatics—The LC-MS/MS data were processed with Pro-
teome Discoverer (Version 1.4.1.14, Thermo Fisher Scientific) and
subjected to database searching using both an in-house Mascot
server (Version 2.2.04, Matrix Science Ltd., London, UK) and the
embedded Sequest HT server with the following criteria: database,
SwissProt Homo Sapiens protein database (updated 15–01-2015,
20193 sequences) with common contaminants; enzyme, trypsin;
maximum missed cleavages, 2; variable modifications included oxi-
dation (Met), acetyl (protein N terminus and lysine(K)), SIA for Cys (SIA
represented the CysPAT tag), deamidation for Asn and Gln. For the
coenrichment experiments, only Mascot was used as search engine,
and beside above parameters, NEM for Cys, phosphorylation (Ser,
Thr, and Tyr), SILAC (Arg10/Lys8) were also included as a variable
modification. The MS and MS/MS results were searched with a pre-
cursor mass tolerance at 10 ppm and a MS/MS mass tolerance at
0.05 Da. The Mascot results were filtered in Proteome Discoverer with
the integrated Percolator algorithm (27) to ensure the false discovery
rate (FDR) less than 0.01. Only peptides identified with high confi-
dence, Mascot score higher than 18 and passed the default score
versus charge state for Sequest HT were accepted. Peptides with
different amino acid sequences or modifications were considered
unique. The quantitative data from the triplicate SILAC labeled HeLa
cells subjected to EGF stimulation was submitted to statistical anal-
ysis. The log2-values of the measured precursor areas were normal-
ized by the median. Phosphosite localization probability was deter-
mined using the PhosphoRS probability algorithm (28). Peptides were
merged with the R Rollup function (http://www.omics.pnl.gov) allow-
ing for one-hit-wonders and using the mean of the normalized areas
for each peptide. Then the mean over the experimental conditions for
each peptide in each replicate was subtracted in order to merge data
from the three replicates. Significant up/down regulated peptides
were defined as peptides with minimum 1.5-fold change, quantified in
at least two of the replicates and with a standard deviation lower than
the 2 median of all the standard deviations of peptides. Annotation
and classification of the identified proteins were facilitated by using
Protein Center (Thermo Fisher Scientific) and the PANTHER Classifi-
cation System (http://www.pantherdb.org/). The detail procedures
were performed as described previously (29). Ingenuity pathway anal-
ysis (IPA) was performed to reveal the protein interaction and signal-
ing pathways.
RESULTS AND DISCUSSION
Development of the CysPAT Chemistry and Test of Cys
Labeling—In this manuscript, a Cysteine-specific Phospho-
nate Adaptable Tag (CysPAT) was synthesized by a reaction
between N-Succinimidyl iodoacetate (SIA) and 2-aminoethyl-
phosphonic acid (2-AEP), in a 1:4 molar ratio, in a DMSO/
TEAB (pH  7.8) solution for 1 h at room temperature to
generate 2-(2-iodoacetamido) ethyl phosphonic acid. Fig. 1A
depicts the chemical scheme for the synthesis. Succinimidyl
iodoacetate (SIA) was selected as it is a small heterobifunc-
tional crosslinker with sulfhydryl- and amine-reactivity
through its iodoacetate- and succinimidyl moiety, respectively
(Fig. 1A). Apart from SIA, we also tested other similar mole-
cules, such as succinimidyl-(4-iodoacetyl)-aminobenzoate as
a viable option for thiol tagging; however SIA showed the
highest labeling performance (data not shown). The SIA mol-
ecule allowed the introduction of a phosphonate functional
group on the Cys residue via alkylation (Fig. 1B), which could
be used for subsequent enrichment using TiO2, a chromato-
graphic resin with high efficiency for enrichment of phosphor-
ylated peptides in phosphoproteomics.
The CysPAT enrichment strategy was developed using a
synthetic Cys peptide (VALRHCLAL, m/z 995.58). The
CysPAT tag was incubated in a 5:1 molar ratio with the
synthetic peptide at room temperature for 1h. The iodoacet-
amide group specifically reacts with the free thiol group of the
Cys residue through alkylation. As monitored by MALDI MS
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the alkylation between the CysPAT tag and the peptide was
highly efficient and led to a 165.02 Da mass increase com-
pared with the unreacted standard Cys peptide (Fig. 2A and
2B). MALDI-MS/MS confirmed that the modification occurred
at the Cys residue (supplemental Fig. S1A). Less than 1% of
the standard peptide reacted with residual iodoacetic acid,
formed by the hydrolysis of the SIA compound (insert Fig. 2B),
illustrating the efficiency of the tagging strategy.
Next the CysPAT-labeled peptide was spiked into a peptide
mixture originating from tryptic digestion of reduced and io-
doacetamide-alkylated bovine serum albumin (BSA) in a 1000
molar excess (see MALDI MS analysis of the mixture in Fig.
2C). The Cys-PAT peptide was subsequently enriched using
TiO2 chromatography, in a similar way as for phosphopep-
tides (20) (Fig. 2D). In the spectrum of the spiked BSA pep-
tides mixture (Fig. 2C), most of the intense peaks are from
known BSA peptides, and the signal of the CysPAT-labeled
peptide is suppressed. However, after TiO2 enrichment, the
signal of the CysPAT-labeled peptide was the most intense
compared with weak signals from some BSA peptides (Fig.
2D). These results indicated that the CysPAT-labeled Cys
peptide can be efficiently enriched using TiO2 chromatogra-
phy with high efficiency and specificity.
Next, the method was applied to peptides derived from
BSA. BSA is a protein containing 35 Cys residues among a
total of 607 amino acids and 34 are in disulfide bridges. After
reduction, alkylation with CysPAT and trypsin digestion, the
peptide mixture was subjected to TiO2 enrichment and the
enriched peptides were further analyzed by nLC-MS/MS.
Subsequent database search revealed that all the Cys pep-
tides were identified with high confidence (1% FDR) (supple-
mental Fig. S2). A representative MS/MS spectrum of a
CysPAT-labeled peptide from BSA is reported in supplemen-
tal Fig. S1B. No neutral loss was observed in the fragment
ions because of the gas phase stability of phosphonate func-
tional group. Interestingly, a diagnostic ion at 224.014 m/z
(C6H11NO4PS) was present in all the MS/MS spectra of
CysPAT-labeled peptides. A possible structure of the diag-
nostic ion is reported in supplemental Fig. S1C.
In order to characterize the chromatographic behavior of
the CysPAT tagged peptides we made a peptide mixture
containing equal amount of CysPAT and iodoacetamide (IAA)-
labeled Cys peptides from BSA. Characterization of the chro-
matographic behavior of this peptide mixture revealed that
the addition of an anionic phosphonate moiety by CysPAT
increased the retention time compared with IAA-labeled Cys
peptides in C18 reversed-phase (RP) chromatographic sepa-
ration (supplemental Fig. S3A and S3B). The chromatographic
shift was linearly dependent on the number of modified Cys
(supplemental Fig. S3B). In addition, the phosphonate moiety
slightly reduced the peptide charge state but did not give
raise to gas-phase beta elimination during CID or HCD frag-
mentation, a phenomenon commonly observed with the
phosphate moiety when fragmenting serine and threonine
phosphorylated peptides, thereby facilitating accurate identi-
fication of the SIA modified peptide and the site for modifica-
tion. Furthermore, because of the phosphonate moiety the
SIA labeled peptides are resistant toward phosphatase treat-
ment enabling a clear distinction between phosphorylated
peptides and SIA labeled peptides if needed.
Analysis of Cys Peptides from HeLa Cells—The CysPAT
strategy was next applied to detect total Cys residuals (in-
cluding both free and reversibly modified Cys) from 500 g
HeLa cell lysates under physiological condition (Fig. 3A). The
proteins were reduced with TCEP, tryptic digested and alky-
lated with the CysPAT tag. Prior to TiO2 enrichment the sam-
ple was dephosphorylated and deglycosylated as both phos-
phopeptides and sialylated glycopeptides have a high affinity
FIG. 1. Chemical synthesis and peptide labeling using the CysPAT tag. A, Synthesis of 2-(2-iodoacetamido) ethyl phosphonic acid
(CysPAT) by reaction between N-Succinimidyl iodoacetate (SIA) and 2-aminoethylphosphonic acid (2-AEP) at 1:5 molar ratio at pH  7.8. B,
Cys peptide labeling was performed through reaction between the free thiol group and the iodo group of CysPAT.
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toward the TiO2 resin (20, 30). The CysPAT tagged peptides
were enriched with TiO2, fractionated with hydrophilic inter-
action liquid chromatography (HILIC), and analyzed with LC-
MS/MS. In total, 7628 unique total peptides were identified of
which 7509 unique Cys peptides (6108 unique Cys sites) were
originating from 2750 proteins (supplemental Table S1). The
enrichment efficiency was 98.4%. In a similar experiment
where the free Cys were blocked with NEM and the reversibly
modified Cys were labeled with CysPAT, a total of 5687
unique Cys peptides were identified from 500 g of HeLa cells
lysate (supplemental Table S2).
Strategy for Simultaneous Enrichment of Cys-containing
Peptides and Phosphopeptides Applied to Study the Effect of
5 min EGF Stimulation of HeLa Cells—As TiO2 chromatogra-
phy is widely used for efficient enrichment of phosphopep-
tides, we next tested if it was possible to perform a simulta-
neous enrichment of phosphopeptides and reversibly
modified CysPAT labeled peptides by TiO2 chromatography.
Such a strategy would allow an investigation of the potential
cross-talk between phosphorylation and Cys modification
from the same sample. Therefore, we designed an experiment
for simultaneous enrichment of phosphopeptides and revers-
ibly modified CysPAT labeled peptides from SILAC labeled
Hela cells subjected to 5 min EGF stimulation (see strategy in
Fig. 3B). Here, the free Cys residues were firstly blocked with
NEM in the cell lysis buffer, then the differentially SILAC
labeled proteins were purified, quantified and equally mixed
(250 g from each cell population). The mixed protein mixture
FIG. 2. CysPAT labeling allows a highly selective enrichment of cysteine-containing peptide using TiO2. MALDI-MS spectra of the A,
standard synthetic Cys peptide; B, CysPAT-labeled peptide. Zoom in the 1045–1065 m/z range shows the presence of a possible side reaction
product with less than 1% intensity; C, CysPAT-labeled peptide spiked in tryptic digest of BSA in a 1:1000 ratio, and D, enriched
CysPAT-labeled peptide by TiO2 from tryptic BSA mixture.
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was reduced with TCEP, tryptic digested, labeled with
CysPAT, and deglycosylated with PNGase F and Sialidase A.
More TiO2 beads than for phosphopeptides were used for
enrichment in order to achieve efficient enrichment of both
types of modified peptides (31). The enriched peptides were
fractionated into 14 fractions using HILIC and analyzed using
the Orbitrap Fusion mass spectrometer.
As expected, both phosphopeptides and CysPAT modified
peptides were simultaneously enriched with the TiO2 resin. In
total, 4802 proteins were identified in this study; they included
3855 proteins containing CysPAT labeled Cys peptides and
2234 proteins identified with phosphopeptides, with 1287
proteins shared between the two groups (Fig. 4A). At the
peptide level, we identified a total of 20408 unique peptides
within the three biological replicates, which include 7339
unique phosphopeptides and 10440 unique CysPAT peptides
(Fig. 4B, supplemental Table S3). A total of 2769 peptides did
not contain the CysPAT and/or phosphorylation modification,
giving enrichment efficiency for both types of modified pep-
tides of 87%. A total of 140 peptides were found to contain
both phosphorylation sites and reversibly modified Cys sites.
This low overlap between phosphopeptides and reversibly
modified Cys peptides is most likely reflecting the fact that
phosphorylation happens through an enzymatic reaction by
kinases, which mostly recognize amino acids on the surface
of the proteins, whereas reversible Cys modifications are
mostly located inside the protein 3-D structure, such as di-
sulfide bonds, which are the main component of reversible
Cys modifications. Thus, phosphorylation sites and reversible
modified Cys are not in close proximity in the protein se-
quence. The enriched peptides also included 723 peptides
with multiple phosphorylation sites and 148 with multiple
CysPAT sites (Fig. 4C). Based on the identified peptides, 8324
unique phosphorylation sites (6093 pS, 1976 pT, 255 pY) and
9008 unique reversibly modified Cys sites (Fig. 4D) were suc-
cessfully mapped, respectively. The information of the iden-
tified unique Cys sites and phosphorylation sites retrieved
from Uniprot database is presented in supplemental Table
S4. Furthermore, phosphopeptides and CysPAT peptides
showed diverse elution patterns during the HILIC fractionation
step (supplemental Fig. S4). Earlier elution of CysPAT labeled
Cys peptides was observed in the HILIC fractionation com-
pared with phosphorylated peptides, indicating that the
CysPAT labeled Cys peptides are generally more hydrophobic
than the phosphopeptides. This could be attributed to the
alkyl chain moiety of the tag that confers more hydrophobic-
FIG. 3.General workflow for CysPAT labeling of complex biological samples. A, Selective detection of total Cys peptides from Hela cells.
B, Coenrichment of reversibly modified Cys peptides and phosphopeptides from SILAC labeled Hela cell subject to 5 min EGF stimulation. All
labeled peptides were enriched with TiO2 before HILIC prefractionation and nLC-MS/MS analysis.
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ity. This different property of phosphopeptides and CysPAT
labeled peptides enables efficient prefractionation using
HILIC chromatography to increase the identification efficiency
while decrease the interference and competition between
both types of peptide subsets during MS characterization in
coenrichment experiments. These results confirmed that the
phosphopeptides and the Cys peptides labeled with CysPAT
can be efficiently simultaneously enriched by a routine TiO2
enrichment method with high enrichment efficiency, and
HILIC prefractionation can partially fractionate these two
types of peptides because of their different hydrophilicity.
According to the Uniprot database some of the reversibly
modified Cys sites were confirmed key sites for zinc finger
structure (39 sites in 32 proteins), iron-sulfur cluster (18 sites
in 14 proteins), S-nitrosylation (16 sites from 13 proteins) and
other important functionalities. The oxidation status of the
conserved Cys residues in these proteins determines the
protein structure and activity (32, 33). The annotated PTM
sites information from Uniprot database was presented in
supplemental Table S4.
Regulation of Phosphorylation and Reversible Cys Modifi-
cation During Short Time EGF Stimulation of HeLa Cells—
Overview of the Analysis—Extracellular EGF stimulation di-
rectly leads to the activation of the epidermal growth factor
receptor (EGFR) through triggering the dimerization and au-
tophosphorylation on key cytoplasmic tyrosine residues of
EGFR (34). It further activated a multitude of downstream
proteins and initiates a cascade of signaling events. These
processes have previously been shown to be regulated by
multiple PTM events, such as phosphorylation, ubiquitination
and acetylation (35). Studies revealed that short term EGF
stimulation (5 min) can lead to the sharply increased phos-
phorylation of EGFR and multiple downstream proteins
whereas the total protein amounts were stable (36, 37). Mean-
while, short term EGF stimulation can result in a transient
increase in the intracellular concentration of H2O2 (38), which
may induce the intracellular oxidative levels, and increase
reversible Cys oxidation. Phosphorylation of EGFR and H2O2
production both reach to highest levels at 5 min in time
courses of EGF stimulation (37, 38), therefore, we applied the
coenrichment method to simultaneously determine the
changes of phosphorylation and reversible Cys oxidation in
SILAC labeled Hela cells subjected to 5 min EGF stimulation
(Fig. 3B).
A total of 2255 peptides from 1313 proteins (supplemental
Table S5) were considered as significantly regulated peptides,
which should be quantified in at least two out of three repli-
cates, with more than 1.5-fold change (log2(H/L)  0.59 or 
0.59), and with a standard deviation lower than the median
of the global peptide standard deviation. The summary of
down and up-regulated Cys peptides and phosphopeptides
as well as related proteins are presented in supplemental Fig.
S5. Surprisingly, we identify more regulated Cys peptides
compared with phosphorylated peptides in this study, indi-
cating a substantial modulation of cellular signaling through
reversible Cys modifications. Most of Cys in cells exist in a
balanced condition between free form and reversibly oxidized
form. In this study, we blocked the free thiols, reduce and
enrich the reversibly modified Cys peptides, so the identified
down-regulated Cys peptides indicated that these sites were
FIG. 4. CysPAT strategy allows high efficient coenrichment of Cys peptides and phosphorylated peptides. Venn diagram indicated A,
the identified proteins and B, the unique peptides with or without reversible Cys modification and phosphorylation from the coenrichment
experiment. C, the summary of mapped mono and multi phosphorylation sites and reversibly modified Cys sites, D, PTMs distribution.
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present more as free thiols, conversely, the identified up-
regulated Cys peptides indicated that these sites were more
reversibly oxidized. Three examples of MS/MS spectra from
MCM3, PTP1B and Filamin A are reported in supplemental
Figs. S6, S7, and S8, respectively. As it was only 5 min EGF
stimulation, we assumed that the total protein expression
should not be significantly affected.
The EGFR Network—Our study identified 8 reversibly
modified Cys sites and 3 phosphorylation sites from EGFR
itself. Among these, significant regulation was observed for
Cys157, Cys260, Cys291, Cys307, Cys311 within the extra-
cellular part of EGFR. The Cys sites were all down-regulated
in their reversibly modified form and they are all located in
the cysteine rich domain II or S1of EGFR and form disulfide
bonds with other Cys in the same domain (39). Domain II
contain the dimerization loop which is essential for the
dimerization of EGFR upon EGF stimulation, and in normal
physiological conditions the autoinhibitory intramolecular
domain II-IV interactions can maintain the EGF receptor in
an inactive state by constraining the relative orientation of
ligand binding domains I and III (40). The reversible Cys
modification observed on EGFR could be a result of the
activation of the protein disulfide-isomerase, which can act
as a reductase the cell surface, on which we identified
significant modulation of Cys312 and Cys343. The Cys797
in the EGFR active site, which has previously been shown to
be regulated by H2O2 (41), was not identified in the present
study. The intracellular autophosphorylation site Tyr1172
was confirmed to be phosphorylated at very high level upon 5
min EGF stimulation verifying the autophosphorylation and
EGF stimulation (37).
Protein interaction analysis of the regulated proteins re-
vealed that 21 proteins interacted directly with the EGFR, and
12 proteins showed indirect interaction, as shown in Fig. 5.
The regulated phosphorylation sites and reversibly modified
Cys sites together with their regulation and protein cellular
localization are indicated in the figure. The analysis showed
that many of the phosphorylation sites and reversibly modified
Cys sites from these proteins were significantly regulated by 5
min EGF stimulation. EGFR and 9 other EGFR network pro-
teins were determined to have both regulated phosphoryla-
tion sites and Cys sites, and some of these sites showed
reverse regulation patterns within the same protein, such as
for EGFR, Ras-associated and pleckstrin homology domains-
containing protein 1 (RAPH1) and Annexin A2 (ANXA2) (sup-
plemental Table S6). The minichromosome maintenance
FIG. 5. The regulated PTM sites and related proteins in the EGFR interaction network. The regulated PTM sites together with their
change pattern and protein cellular localization were indicated. For proteins marked in red: with only Cys modification; in yellow: with only
phosphorylation; in orange: with both PTMs. For PTM Sites in green: downregulated; in blue: up-regulated.
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(MCM) protein complex located in the nucleus is required for
initiation and regulation of DNA replication and cell prolifera-
tion, specifically the formation and elongation of the replica-
tion fork (42). This protein complex is part of the EGFR net-
work. For example, it has previously been shown that
activated EGFR can enhance MCM7 phosphorylation and
subsequently DNA replication (43). Here, we identified 10
molecules forming a MCM complex network, including all six
members of the MCM hexamer (MCM2 through MCM7) which
form a ring structure (44). We found that all the changed Cys
sites and phosphorylation sites of the 10 proteins were up-
regulated, indicating increased phosphorylation and reversi-
ble Cys oxidation of MCM complex upon 5 min EGF stimula-
tion, however, the exact biological role of these sites is
unknown.
Another integrated part of the EGFR network is the Protein
tyrosine phosphatases (PTPs) that catalyze the dephosphor-
ylation of phosphotyrosine residues. These enzymes are key
regulators in signal transduction pathways mediated by tyro-
sine phosphorylation, and are involved in the control of cell
growth, proliferation, differentiation, and transformation (45).
The PTPs carry the highly conserved active site motif HC(X)5R
(PTP signature motif), where the histidine and Cys residues
are conserved in PTPs and dual-specific phosphatases
(DUSPs) (46). The HC(X)5R motif is essential for the catalytic
activity of PTPs. PTPs use the free thiol group of the active
Cys site within this motif as the attacking nucleophile to form
a cysteinyl-phosphate enzyme intermediate (47). Mutagene-
sis-directed substitution or oxidation of the Cys residues
would completely abolish PTPs activity (48). In the present
study, the HC(X)5R motif (Fig. 6A) was identified in 36 of our
identified unique Cys peptides from 35 proteins (Supplemen-
tal Table S7), including 6 protein phosphatases, PTPN1/
PTP1B, PTPN2, receptor-like PTPs (PTPRF, PTPRK, PTPRA),
and DUSP23. The reversible form of catalytic Cys sites iden-
tified in PTP1B, PTPRF, and PTPRK were all significantly
down-regulated, indicating they were reduced and these
PTPs were activated. These PTPs were also found in the
interaction network of EGFR (Fig. 6B and 6C), were PTP1B,
PTPN2 and receptor-like PTPs are known to be negative
regulators of the phosphorylation of EGFR, as summarized
and further confirmed by Tarcic et al. (49). In addition, we
identified regulation of Cys49 in Protein tyrosine phosphatase
type IVA 1, which is known to form disulfide bridges with
FIG. 6. HC(X)5R motif logo and representative protein-protein interaction networks. A, Logo of identified putative phosphatase
signature motif HCX5R and related peptides from PTPs as well as their quantification information, the peptides in bold size were significantly
regulated, NA, not available. B, STRING protein-protein interaction network of the PTPN1 and PTPRK phosphatases.
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Cys104 (the phosphocysteine intermediate). This phospha-
tase is strongly associated with the ras homolog family mem-
bers RAC1, RHOC, and RHOA and with ubiquitin (supplemen-
tal Fig. S9).
The results indicated that the reduction of catalytic Cys
sites of PTPs would lead to the activation of PTPs within 5 min
EGF stimulation, which should contribute to the dephosphor-
ylation of EGFR and other proteins in downstream signaling
events of EGFR. The EGF stimulation increase the intracellular
production of ROS, such as H2O2, However, as the catalytic
Cys sites of PTPs were reduced in the stimulation process,
indicating an activation of the PTPs and at the same time we
observed activation of the pathway. These findings could
reflect the fact that we perform a continuous stimulation of the
EGFR where EGF is present all the time. This means that we
will have a constant autophosphorylation of EGFRs and most
likely an increased dephosphorylation at the same time via the
activated PTPs. It would be very interesting to explore the
mechanisms underlying the reduction of the Cys in the active
site of PTPs within the cell with and without constant EGF
stimulation.
PTP1B is a well characterized phosphatase involved in the
regulation of the insulin receptor and EGFR and a therapeutic
target in type 2 diabetes and obesity (50, 51). Here, we iden-
tified 2 reversibly modified Cys sites (Cys 32 and Cys215) and
5 phosphorylation sites (Ser50, Ser295, Ser363, Ser365, and
Ser378) in PTP1B. Oxidation of the Cys215 site in the
HC(X)5R motif would lead to the inactivation of PTP1B, how-
ever, the reversible sulfenylation of Cys215 is a protective
intermediate in the oxidative inhibition of PTP1B, it can pro-
tect the Cys from further irreversible oxidation and may facil-
itate reactivation of PTP1B by biological thiols (52). The ac-
tivity of PTP1B has also been shown to be allosteric regulated
by phosphorylation of the Ser50 residue which results in the
inactivation of this protein (53). Our results showed both the
reversibly modified form of Cys215 and the phosphorylation
of Ser50 was downregulated, thereby the free form of Cys 215
should be increased, and the inhibitory effect of phosphor-
ylation of the Ser50 would be decreased, both events would
contribute to the activation of PTP1B.
Further in the well-known EGFR signaling pathway we ob-
served regulated phosphorylation sites or Cys sites in four
more proteins (supplemental Table S5, supplemental Fig.
S10), Inositol 1,4,5-trisphosphate receptor type 3 (ITPR3) and
Ras GTPase-activating protein 1(RASA1) with down-regu-
lated Cys sites, mitogen-activated protein kinases (MAPK1
and MAPK3) with up-regulated phosphorylation sites. RASA1,
MAPK1 and MAPK3 are the key molecules in the EGFR-Ras-
Raf-MEK-ERK signaling network, which has been the subject
of intense research and pharmaceutical scrutiny to identify
novel target-based approaches for cancer treatment (54). The
Thr185, Tyr187 of MAPK1 and Thr202, Tyr204 of MAPK3 are
key phosphorylation sites of the Thr-Xaa-Tyr motif in the
MAPK activation loop, MAPKs are activated by phosphoryla-
tion of these two specific amino acids in the activation loop,
and dephosphorylation of the tyrosine residue is sufficient to
inactivate MAPK, blocking its nuclear translocation (55). The
phosphorylation Thr185, Tyr187 of MAPK1 and Thr202,
Tyr204 of MAPK3 were all identified to be up-regulated upon
5 min EGF stimulation, which is consistent with previous
similar phosphoproteomic study (56). The inactivation of
MAPKs can be achieved by PTPs, such as MAPK-PTPs and
DUSPs (55). In particular, DUSP23 can dephosphorylate and
inactivate MAPK3 (57). In this study we found the catalytic
Cys95 of DUSP23 to be more in the free thiol form, indicating
that DUSP23 might also be activated and dephosphorylate
the downstream targets, like MAPK3.
Global Pathway Analysis of Regulated Reversible Cys Pro-
teins—A total of 836 proteins were found to include significant
alteration in the oxidation state of Cys sites. Global STRING
analysis of all up- and down-regulated proteins can be
visualized in Fig. 7 and 8, respectively. From this analysis it is
apparent that a substantial amount of proteins in cellular
networks are modulated by reversible Cys modifications upon
5 min EGF stimulation, most likely because of the increased
generation of H2O2 observed after 5 min stimulation (38).
Many of the proteins have never previously been associated
with EGF signaling or reported to be regulated by reversible
Cys modifications. Brief EGF stimulation of HeLa cells not
only result in regulation of proximal cellular events, such as
the EGF signaling pathway itself and integrin signaling, but
also significant regulation of molecular events within the nu-
cleus, such as chromatin remodeling, DNA condensation,
initiation of cytokinesis and modulation of pre-RNA (Fig. 7 and
8). Interestingly, among the chromatin remodeling cluster ob-
served with increased SIA modification we identify two HDAC
proteins, HDAC 1 and 3, which are key deacetylases for
deacetylation of lysine residues on the N-terminal part of the
core histones (H2A, H2B, H3, and H4). Both Cys sites identi-
fied in HDAC 1 (Cys273) and HDAC 3 (Cys279) was identified
as up-regulated twofold after 5 min EGF stimulation. It has
previously been shown that oxidative reversible modification
of two conserved cysteine residues, corresponding to
Cys(261) and Cys(273) in HDAC1, coincided with attenuation
of histone deacetylase activity, resulting in subsequent
changes in histone H3 and H4 acetylation patterns (58) and
altered gene expression regulation. Our data strongly suggest
regulation of deacetylation activity of HDAC 1 and 3 after brief
EGF stimulation.
In addition, we identified 61 Cys sites on 40 proteins from
the mitochondria that show alteration in reversible Cys mod-
ification. These proteins are involved in the electron transport
chain and oxidative phosphorylation and in protection against
oxidative stress (e.g. Persulfide dioxygenase ETHE1 and
Phospholipid hydroperoxide glutathione peroxidase, (supple-
mental Fig. S11).
Furthermore, we identified a larger number of proteins, with
regulated reversible Cys modifications, that are involved in
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general redox regulation in the cell, as illustrated by the
STRING network in supplemental Fig. S12. Of these, thiore-
doxin was identified with one significantly down-regulated
Cys site (Cys73). This site has previously been shown to be
nitrosylated (59) and it can function as donor for nitrosylation
of target proteins, such as Caspase-3, which lead to inhibition
of apoptosis (59).
Some of the most abundant protein networks observed in
the down-regulated reversible modified Cys data set are re-
lated with protein translation, such as ribosomal proteins,
translation initiation and elongation factors and tRNA synthe-
tases (Fig. 8). Surprisingly, a total of 34 Cys sites on 13 tRNA
synthetases showed differential regulation, 32 down regu-
lated, in their Cys site, after brief EGF stimulation. Aminoacyl-
FIG. 7. Protein-protein interaction
network of proteins identified with up-
regulated reversibly oxidized cysteine
residues SILAC-ratios upon EGF stim-
ulation of Hela cells. Several biological
processes were identified such as: (1)
DNA replication (transcription factors,
polymerases and the Minichromosome
maintenance complex); (2) Pre-mRNA
processing transportation and splicing;
(3) Glycolysis; (4) Chromatin remodeling,
(deacetylases and DNA methyltrans-
ferases); (5) Cytokinesis and sister chro-
matid cohesion and 6) DNA condensin
complex.
FIG. 8. Protein-protein interaction
network of proteins identified with
downregulated reversibly oxidized
cysteine residues SILAC-ratios upon
EGF stimulation of Hela cells. (1) In-
tegrin signaling with the cytoskeleton
networks; (2) EGFR signaling mole-
cules; (3) tRNA synthetases; (4) Protein
translation; ribosomes, initiation and
elongation factors; (5) Ribosomal bio-
synthesis and RNA splicing; (6) Fatty
acid-oxidation.
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tRNA synthetases catalyze the process of aminoacylation of
tRNAs by joining an amino acid to its correct tRNA, that can
then be used in the protein translation machinery. The large
amount of regulated tRNA synthetases suggests that Cys
modulation is a common and general way of regulating the
activity of this enzyme group in mammalian cells. A few pre-
vious studies of tRNA synthetases from prokaryotes have
suggested a role for cysteine residues in the aminoacylation
process (60). In one of the most previous study they found
that air oxidation increased the Ser-tRNAThr level in the pres-
ence of elongation factor Tu and that Cys182 forms a putative
metal binding site with three conserved histidine residues
(His73, His77, and His186) (61). However, because the con-
tent of cysteine in general is higher in the mammalian tRNA
synthetases compared with the prokaryote ones, we propose
that reversible Cys modification of tRNA synthetases via ox-
idative species, such as H2O2, is the key regulator of the
aminoacylation process in eukaryote systems and especially
in conjunction with cellular signaling where new protein has to
be generated fast.
Previously, reversible Cys modification has been proposed
to be involved in cross talking with various other PTMs, such
as phosphorylation, acetylation and ubiquitination (62). How-
ever, beside the abovementioned tyrosine-phosphatases,
very little evidence of this cross talking in cellular signaling has
been presented. In the present study, we observed alteration
in Cys modifications of several enzyme groups responsible for
the addition and removal of post-translational modifications,
such as for the phosphatases described above. Among these,
we identified a total of 30 kinases that showed alteration in
reversible Cys modification, including GSK3A, PRKAR1A,
MAP2K2, DYRK1B, ERBB2, ARAF, and SLK, further support-
ing the idea of a substantial cross-talking between Cys mod-
ification and phosphorylation. Furthermore, we observed sig-
nificant alteration of reversible Cys modification of enzymes
participating in Acetylation (HDAC1 and 3, KAT6B, KAT7, and
HAT1), O-GlcNAcylation (OGT), Neddylation and Ubiquitina-
tion (see supplemental Fig. S13) and Glycosylation (GALB1,
MGEA5, GALNT2, STT3A, ALG9). These results suggest that
the reversible Cys modification is cross-talking with a sub-
stantial amount of PTMs during brief cellular stimulation, plac-
ing this modification as a central part of cellular signaling, at a
level we previously did not anticipate. However, the exact way
this cross talk is conducted is still relative unknown unless for
the enzyme where a direct activity switch (tyrosine phospha-
tases) or a metal conjunction is observed which include a free
Cys residue.
CONCLUSION
In this study, we have developed a new phosphonate tag
capable of tagging cysteine containing peptides and demon-
strated with standard peptides and complex mixtures that the
strategy has a very high efficiency and specificity. In addition,
because of the high affinity of the phosphonate tag and phos-
phate groups for TiO2, the new tagging of Cys peptides allow
the simultaneous enrichment of phosphopeptides and Cys
peptides which offers an excellent tool for studying the cross-
talk between phosphorylation and Cys redox modifications. In
principle, other enrichment methods developed for phospho-
peptides should also be applicable to enrich the Cys peptides
labeled with CysPAT. The CysPAT strategy has several ad-
vantageous features such as (1) it is easy and cheap to
synthesize the tagging reagent, (2) we observed an almost
complete labeling of the Cys peptides with minor detectable
side reactions, (3) high enrichment efficiency using TiO2, (4) no
side effects on peptide solubility, chromatographic and
MS/MS behavior, and (5) the possibility of simultaneous char-
acterization of different PTMs which has an affinity toward
TiO2, such as phosphopeptides and sialylated glycopeptides,
offer the possibility to characterize the cross-talk of these
PTMs from the same sample.
In the study of the brief EGF stimulation of HeLa cells
presented here we clearly show a substantial modulation of
reversible modified Cys sites presumable caused by the in-
crease in H2O2 production after EGFR stimulation. Very sur-
prisingly, we observe more regulated Cys sites compared with
phosphorylation sites in this well-studied signaling pathway
and many of these are on protein associated with chromatin
remodeling and DNA replication. Furthermore, we observe
regulation of Cys sites in a large number of enzymes that are
associated with dynamic PTMs supporting the idea of revers-
ible Cys modification having substantial cross-talks with other
PTMs. Most of the regulated Cys sites have never been as-
sociated with EGF signaling before and this could open up for
various new ideas to manipulate this pathway, which is very
central in diseases such as cancer.
Overall, we believe that the concept of “phospho-based
adaptable tags” approach will be a valuable tool for research-
ers and will be explored and extended to label other PTMs
and improve the current proteomic toolbox.
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